資源描述：
《瑞信-美股-生物科技行業(yè)-美國(guó)生物科技Q1業(yè)績(jī)預(yù)覽-2020.4.9.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫(kù)。
1、9April2020EquityResearchAmericas
2、UnitedStatesU.S.BiotechnologyCreditSuisseBiotechQBankforQ1EarningsandSpringConferencePrepBiotechnology
3、CommentWeknowyou’rebusy!TohelpyouprepareforQ1earningsseasonandanupcomingroundofResearchAnalystsvirtualhealthcareconferences,we’vepreparedacom
4、prehensivequestionbankaswellasacatalystlistdetailingupcomingeventsacrosstheCreditSuisseU.S.BiotechnologycoverageMartinAuster,M.D.universe.Inadditiontoourtypicalquestionsoncommerciallaunchupdates,pipelineprogress,2123256573financialstanding,etc.,wehaveincludedpointedquestionsab
5、outCOVID-19anditspotentialmartin.auster@credit-suisse.comimpactsoneachcompany.Wehopethishelpsinyourprocess,pleaseletusknowifyouhaveEvanSeigermananyquestionsorfeedback.2123254463evan.seigerman@credit-suisse.comTiagoFauthAnalystBiotechnologyCompanies2123257569tiago.fauth@credit-
6、suisse.comMarkConnolly2123257576mark.connolly@credit-suisse.comThomasDealAusterCoverage2123253719thomasavery.deal@credit-suisse.comMatthewTerwelp,MD2123253493matthew.terwelp@credit-suisse.comSeigermanCoverageFauthCoverageDISCLOSUREAPPENDIXATTHEBACKOFTHISREPORTCONTAINSIMPORTANT
7、DISCLOSURES,ANALYSTCERTIFICATIONS,LEGALENTITYDISCLOSUREANDTHESTATUSOFNON-USANALYSTS.USDisclosure:CreditSuissedoesandseekstodobusinesswithcompaniescoveredinitsresearchreports.Asaresult,investorsshouldbeawarethattheFirmmayhaveaconflictofinterestthatcouldaffecttheobjectivityofthi
8、sreport.Investorsshouldconsiderthisreportasonlyasinglefactorinmakingtheirinvestmentdecision.9April2020TableofContentsSmid-CapBiotechTeamCoverage3Acceleron–XLRN.........................................................................................................4Alexion–ALXN
9、.............................................................................................................6AnaptysBio–ANAB.....................................................................................................10Apellis–APLS.....................................
10、.............................................................
